Man­u­fac­tur­ing roundup: Mil­li­pore­Sig­ma launch­es new AAV plat­form; New IV flu­id man­u­fac­tur­ing fa­cil­i­ty is com­ing to cen­tral Flori­da

Mer­ck KGaA’s Mil­li­pore­Sig­ma has launched a new AAV pro­duc­tion plat­form.

The plat­form will en­able the CD­MO to pro­vide vi­ral vec­tor man­u­fac­tur­ing in­clud­ing AAV, lentivi­ral, CD­MO, CTO and process de­vel­op­ment faster while re­duc­ing de­vel­op­ment time and costs.

“By in­creas­ing dose yields and dra­mat­i­cal­ly re­duc­ing process de­vel­op­ment time, our Viru­s­Ex­press 293 AAV Pro­duc­tion Plat­form will ac­cel­er­ate man­u­fac­tur­ing of these ther­a­pies, ul­ti­mate­ly de­liv­er­ing life­sav­ing treat­ments to pa­tients faster,” said Dirk Lange, head of life sci­ence ser­vices of Mer­ck KGaA, in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER